Deutsche Bank Reiterates Buy on Bristol-Myers Squibb

Deutsche Bank maintains its Buy rating on Bristol-Myers Squibb Company (NYSE: BMY) as Eliquis is granted priority review.

Deutsche Bank comments that the company “had requested expedited review based upon the ARISTOTLE study which demonstrated that Eliquis was SUPERIOR to warfarin, and had a survival benefit. We don't think it was baked into general expectations that an expedited review would be granted, hence the drug likely gets on the market six months earlier than many had expected.”

BMY closed at $31.11 on Monday.